A Review of the Impact of COVID-19 on Male Reproduction, and its Implications on Assisted Reproductive Technology Services

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became an established pandemic in 2020. The presence of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in male reproductive organ are considered as a potential for susceptibility of these organs to SARS-CoV-2 infection. Review: Spermatogonia are the only cells that express ACE2 and TMPRSS2 in the testis, but the cells which co-express both genes are rare (0.05% of cells). Based on this co-expression, sperm are unlikely to be susceptible to infection by SARS-CoV-2. However, the co-expression of receptor basigin (BSG/CD147) and cathepsin L (CTSL) in primary spermatocytes, Leydig cells, myoid cells, endothelial cells, and spermatogonia might increase the testicular susceptibility to this viral infection. Testicular pain and discomfort have been reported in coronavirus disease 2019 (COVID-19) patients. Postmortem examination also reported seminiferous tubular injury, reduced Leydig cells, and mild lymphocytic inflammation in COVID-19 patients. Compensated hypogonadism has been documented while the impact of COVID-19 on the semen quality is inconclusive. There is only one study that reported the presence of SARS-CoV-2 RNA in semen but, is not supported by other studies with better methods. The association between SARS-CoV-2 and assisted reproductive technology (ART) outcome is surrounded by some uncertainties. Recommendations have been made to reduce the risk of viral transmission to patients, staff, gametes, and embryos. Summary: There is no definite correlation between SARS-CoV-2 infection and male reproductive system. However, a high level of vigilance is still required in services which involve the reproductive system.